Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD
Open Access
- 20 July 2016
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 16 (1) , 1-13
Abstract
Abediterol is a novel, once-daily long-acting β2-agonist in development for the treatment of chronic obstructive pulmonary disease (COPD) and asthma in combination with an anti-inflammatory agent. This Phase IIa, randomised, double-blind, crossover study investigated the bronchodilation, safety, tolerability and pharmacokinetics of abediterol in patients with moderate to severe COPD. Seventy patients (aged ≥40 years, Global initiative for chronic Obstructive Lung Disease Stage II/III) were randomised (1:1:1:1:1:1) to single doses of abediterol 0.625, 2.5, 5 or 10 μg, indacaterol 150 μg or placebo. Spirometry was performed up to 36 h post-dose. Pharmacokinetics were assessed in a subset of patients (N = 20). Safety and tolerability were evaluated throughout the study. Abediterol (all doses) significantly improved change from baseline in trough forced expiratory volume in 1 s (FEV1) compared with placebo (0.102, 0.203, 0.233 and 0.259 L for abediterol 0.625, 2.5, 5 and 10 μg, respectively; all p < 0.0001; primary endpoint). Abediterol 2.5, 5 and 10 μg significantly improved trough FEV1 compared with indacaterol 150 μg (0.092, 0.122 and 0.148 L, respectively; all p < 0.0001). Improvements in bronchodilation were maintained at all time points post-dose versus placebo (all abediterol doses) and from 15 or 30 min post-dose versus indacaterol 150 μg with abediterol 2.5, 5 and 10 μg (all p < 0.05). Abediterol had low systemic exposure; incidence of treatment-emergent adverse events was similar between treatment groups. All doses of abediterol (0.625–10 μg) provided clinically and statistically significant, dose-dependent improvements in bronchodilation versus placebo, and abediterol 2.5, 5 and 10 μg gave significant improvements versus indacaterol. All doses of abediterol were safe and well tolerated in patients with COPD. Clinicaltrials.gov NCT01425814 . Registered 29 August 2011.Keywords
This publication has 14 references indexed in Scilit:
- Abediterol (LAS100977), a novel long-acting β2-agonist: Efficacy, safety and tolerability in persistent asthmaRespiratory Medicine, 2014
- First‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long‐acting Β2‐agonistThe Journal of Clinical Pharmacology, 2014
- Inhaled corticosteroids for chronic obstructive pulmonary diseaseExpert Opinion on Pharmacotherapy, 2013
- Pharmacological Characterization of Abediterol, a Novel Inhaled β2-Adrenoceptor Agonist with Long Duration of Action and a Favorable Safety Profile in Preclinical ModelsThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Pharmacology and Therapeutics of BronchodilatorsPharmacological Reviews, 2012
- β2‐adrenoceptor agonists: current and future directionBritish Journal of Pharmacology, 2011
- Daily Physical Activity in Patients with Chronic Obstructive Pulmonary Disease Is Mainly Associated with Dynamic HyperinflationAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Activity Limitation and Quality of life In COPDCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2007
- The Connection Between Chronic Obstructive Pulmonary Disease Symptoms and Hyperinflation and Its Impact on Exercise and FunctionThe American Journal of Medicine, 2006